CD8A and ductal breast carcinoma in situ: Despite significant increases in total T cells and CD8+ T cells following intralesional anti-PD-1 therapy in this study, we did not observe an anti-tumor response as measured by a decrease in tumor cell proliferation, an increase in tumor cell apoptosis, or a decrease in DCIS volume kinetics measured with MRI.